Clinical Trial Update: Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated intravitreal ranibizumab for radiation retinopathy after plaque brachytherapy for choroidal melanoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Melanoma
• Radiation Retinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: The New York Eye Cancer Center | Conditions: Radiation Retinopathy, Choroidal Melanoma | Phase 1 | Status: COMPLETED